Low cost, Broad Spectrum Cancer Vaccine Targeting Human Papillomavirus

针对人乳头瘤病毒的低成本、广谱癌症疫苗

基本信息

  • 批准号:
    10650067
  • 负责人:
  • 金额:
    $ 12.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-07-01 至 2025-03-31
  • 项目状态:
    未结题

项目摘要

Project Summary. Human papillomavirus (HPV) is a major public health concern due to 1) its implication in cancers of the anus, cervix, oropharynx, penis, vulva, and vagina; 2) global economic burden, and 3) vastly disproportionate impact on low-to-middle-income countries (LMIC). HPV-related cancers are responsible for 4.5% of all new cancer cases worldwide, 90% of HPV-related cervical cancer deaths occur in LMIC, and only 1% of LMIC have vaccination programs with limited breadth of protection. The most broadly protective vaccine on the market, Merck’s Gardasil-9, only protects against nine HPV strains and does not protect against strains that are prevalent in LMIC. Current vaccines are also costly and challenging to distribute to LMIC due to their thermal stability and 3-dose regimen. The limitations of current vaccines and burden of HPV on LMIC underscores the need for new cheaper HPV vaccines that can be effectively deployed in LMIC. VaxSyna, Inc addresses this need with a HPV vaccine that is low-cost, broadly protective, and efficacious with a targeted two- dose schedule. Our vaccine candidate displays the highly conserved HPV L2 antigen on our patented platform that uses virus like particles (VLP) and recombinant immune complexes (RIC). The HPV L2 antigen has been shown to protect against up to 22 types of HPV in mice and rabbits and has been evaluated in human phase I trials. Our vaccine is produced using an optimized plant expression system that lowers the manufacturing cost (estimated at less than $0.5/dose vs. $160/dose for Gardasil-9), thereby producing high levels of proteins in 4-5 days without human or animal pathogen contamination. Preclinical, mouse vaccination studies with our candidate have confirmed its efficacy in generating high antibody titers and viral neutralization in as little as two doses. Further tests of our vaccine platform have shown that protective immunity is possible without the need of a chemical adjuvant. The goal of our STTR phase I project is to conduct proof-of-concept studies to characterize the formulation of VaxSyna’s HPV cancer vaccine as a broad-spectrum HPV vaccine that targets all clinically relevant HPVs. Temperature stability is an important characteristic for vaccines that are targeted for LMIC. As such, our parent award Aim 1 will assess the thermal stability of both our VLP and RIC vaccine components. For the parent ward Aim 2 will compare the antibody and neutralizing antibody titers produced after mouse vaccination with varying ratios of VLP to RIC as compared to Gardasil-9. Proposed administrative supplement Aim 3 will evaluate the success of VaxSyna’s HPV vaccine to confer protective immunity against cottontail rabbit papillomavirus in the HPV-standard animal model New Zealand white rabbits by measuring antibody, neutralizing antibody, cellular responses, and papilloma geometric volume. The successful completion of this Phase I project is critical to initiate our proposed Phase II studies involving pre-IND GMP manufacturing and animal toxicology studies. Upon successful approval of VaxSyna’s HPV vaccine, our advantages of low costs and broad-spectrum protection will position VaxSyna to prevent HPV-caused cancers for individuals in LMIC.
项目摘要。人乳头瘤病毒(HPV)是一个主要的公共卫生问题,因为1)它在 肛门癌、子宫颈癌、口咽癌、阴茎癌、外阴癌和阴道癌;2)全球经济负担;3)巨大的 对中低收入国家(LMIC)的影响不成比例。与HPV相关的癌症是 全世界4.5%的新癌症病例,90%与HPV相关的宫颈癌死亡发生在LMIC,并且只有 1%的LMIC有疫苗接种计划,但保护范围有限。保护性最广的疫苗 在市场上,默克公司的Gardasil-9只对九种HPV病毒株有保护作用,而对病毒株没有保护作用 在LMIC中很普遍。目前的疫苗分发给LMIC也是昂贵和具有挑战性的,因为它们 热稳定性和3剂方案。现有疫苗的局限性和HPV对LMIC的负担 强调需要能够有效地在LMIC部署的新的更便宜的HPV疫苗。VaxSyna,Inc. 解决这一需要的是一种低成本、广泛保护和有效的HPV疫苗,它具有靶向的两种- 剂量表。我们的候选疫苗在我们的专利平台上展示高度保守的HPV L2抗原 使用病毒样颗粒(VLP)和重组免疫复合体(RIC)。人乳头瘤病毒L2抗原已经 在小鼠和兔子身上显示了对多达22种HPV的保护作用,并已在人类I期进行了评估 审判。我们的疫苗是使用优化的植物表达系统生产的,该系统降低了制造成本 (估计不到0.5美元/剂,而Gardasil-9为160美元/剂),从而在4-5个月中产生高水平的蛋白质 没有人类或动物病原体污染的日子。我们的临床前、小鼠疫苗研究 候选人已经证实了它在产生高抗体效价和在短短两年内中和病毒的有效性 剂量。我们疫苗平台的进一步测试表明,保护性免疫是可能的,而不需要 一种化学佐剂。我们STTR第一阶段项目的目标是进行概念验证研究,以 VaxSyna公司的HPV癌症疫苗的配方是一种针对所有临床患者的广谱HPV疫苗 相关的HPV。温度稳定性是针对LMIC的疫苗的重要特征。AS 这样,我们的母公司奖Aim 1将评估我们的VLP和RIC疫苗组件的热稳定性。为 家长Ward Aim 2将比较小鼠产生的抗体和中和抗体效价 与Gardasil-9相比,VLP和RIC比例不同的疫苗接种。拟议的行政补充 目的3将评估VaxSyna的HPV疫苗对棉尾兔产生保护性免疫的成功 HPV标准动物模型新西兰大白兔乳头瘤病毒抗体测定、中和 抗体、细胞反应和乳头状瘤几何体积。本项目一期工程顺利竣工 对启动我们提议的涉及前IND GMP制造和动物毒理学的第二阶段研究至关重要 学习。在成功批准VaxSyna的HPV疫苗后,我们的低成本和广谱的优势 保护将使VaxSyna定位为LMIC中的个人预防HPV引起的癌症。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mary Pardhe其他文献

Mary Pardhe的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mary Pardhe', 18)}}的其他基金

Low cost, Broad Spectrum Cancer Vaccine Targeting Human Papillomavirus
针对人乳头瘤病毒的低成本、广谱癌症疫苗
  • 批准号:
    10477108
  • 财政年份:
    2022
  • 资助金额:
    $ 12.13万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 12.13万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.13万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 12.13万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.13万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 12.13万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 12.13万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.13万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 12.13万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 12.13万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.13万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了